Understanding the Omicron Variant Impact in Healthcare Workers: Insights from the Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf) on Risk Factors for Breakthrough and Reinfections.

Autor: Janke C; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany., Rubio-Acero R; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany., Weigert M; Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany.; Munich Center for Machine Learning (MCML), 80539 Munich, Germany., Reinkemeyer C; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany., Khazaei Y; Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany., Kleinlein L; Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany., Le Gleut R; Institute of Computational Biology, Helmholtz Munich, 85764 Neuherberg, Germany.; Core Facility Statistical Consulting, Helmholtz Munich, 85764 Neuherberg, Germany., Radon K; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU University Hospital, LMU Munich, 80336 Munich, Germany.; Center for International Health (CIH), LMU University Hospital, LMU Munich, 80336 Munich, Germany.; Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337 Munich, Germany., Hannes M; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Unit Global Health, Helmholtz Zentrum München, German Research Centre for Environmental Health (HMGU), 85764 Neuherberg, Germany., Picasso F; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany., Lucke AE; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany., Plank M; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany., Kotta IC; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany., Paunovic I; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany., Zhelyazkova A; Institut für Notfallmedizin und Medizinmanagement (INM), LMU Klinikum, LMU München, 80336 Munich, Germany., Noreña I; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany., Winter S; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany., Hoelscher M; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.; Center for International Health (CIH), LMU University Hospital, LMU Munich, 80336 Munich, Germany.; Unit Global Health, Helmholtz Zentrum München, German Research Centre for Environmental Health (HMGU), 85764 Neuherberg, Germany.; German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany., Wieser A; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.; German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany.; Max Von Pettenkofer Institute, Faculty of Medicine, LMU Munich, 80336 Munich, Germany., Küchenhoff H; Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany., Castelletti N; Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany.; Institute of Radiation Medicine, Helmholtz Zentrum München, 85764 Neuherberg, Germany., On Behalf Of The Orchestra Working Group
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2024 Sep 30; Vol. 16 (10). Date of Electronic Publication: 2024 Sep 30.
DOI: 10.3390/v16101556
Abstrakt: This study analyzes immune responses to SARS-CoV-2 vaccination and infection, including asymptomatic cases, focusing on infection risks during the Omicron wave, particularly among high-risk healthcare workers. In the KoCo-Impf study, we monitored 6088 vaccinated participants in Munich aged 18 and above. From 13 May to 31 July 2022, 2351 participants were follow-uped. Logistic regression models evaluated primary, secondary, and breakthrough infections (BTIs). Roche Elecsys ® Anti-SARS-CoV-2 assays detected prior infections (via anti-Nucleocapsid antibodies) and assessed vaccination/infection impact (via anti-Spike antibodies) using dried blood spots. Our findings revealed an anti-Nucleocapsid seroprevalence of 44.1%. BTIs occurred in 38.8% of participants, with reinfections in 48.0%. Follow-up participation was inversely associated with current smoking and non-vaccination, while significantly increasing with age and receipt of three vaccine doses. Larger household sizes and younger age increased infection risks, whereas multiple vaccinations and older age reduced them. Household size and specific institutional subgroups were risk factors for BTIs. The anti-Nucleocapsid value prior to the second infection was significantly associated with reinfection risk. Institutional subgroups influenced all models, underscoring the importance of tailored outbreak responses. The KoCo-Impf study underscores the importance of vaccination, demographic factors, and institutional settings in understanding SARS-CoV-2 infection risks during the Omicron wave.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje